Expression and drug resistance of EGFR in targeted therapy of non-small cell lung cancer

VernacularTitle:EGFR在非小细胞肺癌靶向治疗中的表达及耐药性
Author: Siyuan DENG ¹ ; Xu ZHU ; Jiarong XIAO
Author Information

1. 贵州医科大学，贵阳　550001
Keywords: Non-small cell lung cancer; Epidermal growth factor receptor; Tyrosine kinase inhibitor; Drug resistance
From: Chinese Journal of Endocrine Surgery 2023;17(3):370-372
CountryChina
Language:Chinese
Abstract: Lung cancer is one of the malignant tumors with the highest morbidity and mortality. Epidermal growth factor receptor is expressed in the majority of non-small cell lung cancer tumor cells, making it possible to give these patients more precise and targeted therapies. The mechanisms of abnormal EGFR regulation are closely related to the efficacy of targeted therapy and the occurrence of drug resistance. Therefore, this review will review the expression mechanism of EGFR in NSCLC and the acquired drug resistance of epidermal growth factor receptor tyrosine kinase inhibitor after treatment of NSCLC.